Srinivas K. Chunduru

3.3k total citations · 1 hit paper
42 papers, 2.3k citations indexed

About

Srinivas K. Chunduru is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Srinivas K. Chunduru has authored 42 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 12 papers in Oncology and 12 papers in Immunology. Recurrent topics in Srinivas K. Chunduru's work include Cell death mechanisms and regulation (11 papers), Ubiquitin and proteasome pathways (7 papers) and Hepatitis B Virus Studies (7 papers). Srinivas K. Chunduru is often cited by papers focused on Cell death mechanisms and regulation (11 papers), Ubiquitin and proteasome pathways (7 papers) and Hepatitis B Virus Studies (7 papers). Srinivas K. Chunduru collaborates with scholars based in United States, Australia and Switzerland. Srinivas K. Chunduru's co-authors include Mark A. McKinlay, Christopher A. Benetatos, Stephen M. Condon, John Silke, David L. Vaux, W. Wei‐Lynn Wong, James E. Vince, Diep Chau, Pascal Schneider and Robert Brink and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Srinivas K. Chunduru

42 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis

2007 879 citations James E. Vince, W. Wei‐Lynn Wong et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Srinivas K. Chunduru United States	18	1.6k	640	460	434	337	42	2.3k
Chiang J. Li United States	21	1.7k 1.0×	439 0.7×	391 0.8×	712 1.6×	230 0.7×	42	2.8k
Qui Phung United States	22	1.8k 1.1×	1.5k 2.4×	377 0.8×	906 2.1×	308 0.9×	29	3.2k
Ueli Nachbur Australia	23	1.7k 1.1×	1.2k 1.8×	597 1.3×	415 1.0×	488 1.4×	34	2.5k
Simon R. Green United States	23	2.1k 1.3×	386 0.6×	230 0.5×	692 1.6×	243 0.7×	44	2.8k
Luigi Aurisicchio Italy	32	1.4k 0.9×	1.0k 1.6×	461 1.0×	966 2.2×	174 0.5×	107	3.0k
Fred W. Perrino United States	33	2.6k 1.6×	1.4k 2.3×	344 0.7×	374 0.9×	361 1.1×	75	3.8k
T. Jesse Kwoh United States	22	1.3k 0.8×	380 0.6×	133 0.3×	294 0.7×	426 1.3×	41	2.4k
Petra Neddermann Italy	27	1.8k 1.2×	507 0.8×	125 0.3×	483 1.1×	820 2.4×	36	3.2k
Yves Collette France	36	1.7k 1.1×	1.5k 2.3×	332 0.7×	621 1.4×	319 0.9×	90	3.6k
Jiwu Wei China	25	941 0.6×	475 0.7×	476 1.0×	527 1.2×	248 0.7×	59	1.9k

Countries citing papers authored by Srinivas K. Chunduru

Since Specialization

Citations

This map shows the geographic impact of Srinivas K. Chunduru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srinivas K. Chunduru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srinivas K. Chunduru more than expected).

Fields of papers citing papers by Srinivas K. Chunduru

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srinivas K. Chunduru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srinivas K. Chunduru. The network helps show where Srinivas K. Chunduru may publish in the future.

Co-authorship network of co-authors of Srinivas K. Chunduru

This figure shows the co-authorship network connecting the top 25 collaborators of Srinivas K. Chunduru. A scholar is included among the top collaborators of Srinivas K. Chunduru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srinivas K. Chunduru. Srinivas K. Chunduru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Diab, Adi, Paolo A. Ascierto, Reham Abdel‐Wahab, et al.. (2024). Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).. Journal of Clinical Oncology. 42(17_suppl). LBA9516–LBA9516. 2 indexed citations

Kim, Yoo Jung, Elena Schiopu, Tahseen Mozaffar, et al.. (2021). AB016. A double-blind, placebo-controlled, phase 2 trial of a novel toll-like receptor 7/8/9 antagonist (IMO-8400) in dermatomyositis. Annals of Translational Medicine. 9(5). AB016–AB016. 1 indexed citations

Babiker, Hani M., Erkut Borazanci, Vivek Subbiah, et al.. (2020). 1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours. Annals of Oncology. 31. S711–S712. 2 indexed citations

Kim, Yoo Jung, Elena Schiopu, Katalin Dankó, et al.. (2020). A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis. Journal of the American Academy of Dermatology. 84(4). 1160–1162. 13 indexed citations

Schiopu, Elena, Tahseen Mozaffar, Srinivas K. Chunduru, et al.. (2019). LB1115 A double-blind, placebo-controlled, phase 2 trial of IMO-8400, a novel toll-like receptor 7/8/9 antagonist, in dermatomyositis. Journal of Investigative Dermatology. 139(9). B18–B18. 2 indexed citations

Tanzer, Maria C., Nufail Khan, James Rickard, et al.. (2017). Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways. Cell Death and Differentiation. 24(3). 481–491. 38 indexed citations

Kapoor, Gurpreet S., Christopher A. Benetatos, Yasuhiro Mitsuuchi, et al.. (2014). Abstract 2278: The SMAC-mimetic birinapant regulates autocrine TNF production by caspase-8:RIPK1 complex via p38MAPK pathway. Cancer Research. 74(19_Supplement). 2278–2278. 1 indexed citations

Krepler, Clemens, Srinivas K. Chunduru, Molly B. Halloran, et al.. (2013). The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells. Clinical Cancer Research. 19(7). 1784–1794. 79 indexed citations

Amaravadi, Ravi K., Russell J. Schilder, Grace K. Dy, et al.. (2011). Abstract LB-406: Phase 1 study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity. Cancer Research. 71(8_Supplement). LB–406. 17 indexed citations

10.

LaPorte, Matthew G., Charles W. Blackledge, Lara K. Leister, et al.. (2010). The discovery and structure–activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase. Bioorganic & Medicinal Chemistry Letters. 20(9). 2968–2973. 33 indexed citations

11.

Vince, James E., Diep Chau, Bernard A. Callus, et al.. (2008). TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1–TRAF2 complex to sensitize tumor cells to TNFα. The Journal of Cell Biology. 182(1). 171–184. 209 indexed citations

12.

Vince, James E., Diep Chau, Bernard A. Callus, et al.. (2008). TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1–TRAF2 complex to sensitize tumor cells to TNFα. The Journal of Experimental Medicine. 205(8). i18–i18. 1 indexed citations

13.

Vince, James E., W. Wei‐Lynn Wong, Nufail Khan, et al.. (2007). IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis. Cell. 131(4). 682–693. 879 indexed citations breakdown →

14.

LaPorte, Matthew G., Lara K. Leister, Charles Faust, et al.. (2005). Tetrahydrobenzothiophene inhibitors of hepatitis C virus NS5B polymerase. Bioorganic & Medicinal Chemistry Letters. 16(1). 100–103. 8 indexed citations

15.

Lewis, William S., Vivian Cody, Nikolai Galitsky, et al.. (1995). Methotrexate-resistant Variants of Human Dihydrofolate Reductase with Substitutions of Leucine 22. Journal of Biological Chemistry. 270(10). 5057–5064. 124 indexed citations

16.

Chunduru, Srinivas K., James R. Appleman, & Raymond L. Blakley. (1993). Activity of Human DNA Polymerases α and β with 2-Chloro-2′-deoxyadenosine 5′-Triphosphate as a Substrate and Quantitative Effects of Incorporation on Chain Extension. Archives of Biochemistry and Biophysics. 302(1). 19–30. 20 indexed citations

17.

Blakley, Raymond L., James R. Appleman, Srinivas K. Chunduru, et al.. (1993). Mutations of Human Dihydrofolate Reductase Causing Decreased Inhibition by Methotrexate. Advances in experimental medicine and biology. 338. 473–479. 2 indexed citations

18.

Chunduru, Srinivas K., James R. Appleman, & Raymond L. Blakley. (1993). Kinetic Investigation of Methotrexate Resistant Human Dihydrofolate Reductase (hDHFR) Mutants at PHE31. Advances in experimental medicine and biology. 338. 507–510. 2 indexed citations

19.

Mrachko, Gregory T., et al.. (1992). The pH dependence of the kinetic parameters of ketol acid reductoisomerase indicates a proton shuttle mechanism for alkyl migration. Archives of Biochemistry and Biophysics. 294(2). 446–453. 15 indexed citations

20.

Chunduru, Srinivas K., et al.. (1989). Mechanism of ketol acid reductoisomerase. Steady-state analysis and metal ion requirement. Biochemistry. 28(2). 486–493. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact